SCHEMBL31023751

SCHEMBL31023751

Cc1ccc2c(c1)nnn2C=O

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KCNMA1 Q12791 2/20 0.44
ALDH1A1 P00352 5/20 0.39
LMNA P02545 3/20 0.39
TSHR P16473 1/20 0.39
RAB9A P51151 2/20 0.38
NAMPT P43490 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
POLB P06746 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
GAA P10253 2/20 0.36
MAPT P10636 3/20 0.36
FGFR1 P11362 1/20 0.36
HCAR3 P49019 1/20 0.36
KDM4E B2RXH2 2/20 0.36
MAPK1 P28482 1/20 0.36
HTT P42858 1/20 0.36
HSD17B10 Q99714 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31023980 0.79 CHEK1 (0.50) KCNMA1RAB9AMEN1KMT2AGAA
SCHEMBL11270062 0.75 KCNMA1 (0.46) KCNMA1ALDH1A1LMNATSHRRAB9A
SCHEMBL221980 0.73 RAB9A (0.53) KCNMA1ALDH1A1TSHRRAB9AKMT2A
SCHEMBL22084279 0.73 KCNMA1 (0.45) KCNMA1ALDH1A1LMNATSHRRAB9A
SCHEMBL435034 0.73 HCAR3 (0.56) KCNMA1ALDH1A1RAB9AMEN1KMT2A
SCHEMBL24296701 0.72 KCNMA1 (0.44) KCNMA1ALDH1A1LMNATSHRRAB9A
SCHEMBL5968408 0.72 KCNMA1 (0.44) KCNMA1ALDH1A1LMNATSHRRAB9A
SCHEMBL1814827 0.72 ALDH1A1 (0.53) KCNMA1ALDH1A1LMNATSHRRAB9A
SCHEMBL9489077 0.72 KCNMA1 (0.44) KCNMA1ALDH1A1LMNATSHRRAB9A
SCHEMBL6743405 0.72 KCNMA1 (0.44) KCNMA1ALDH1A1LMNATSHRRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12378231-B2 Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof APOGEE PHARMACEUTICALS, INC. (CA) 2025-08-05 US claimed
EP-4665718-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF Apogee Pharmaceuticals, Inc. (CA) 2025-12-24 EP disclosed
US-12378231-B2 Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof APOGEE PHARMACEUTICALS, INC. (CA) 2025-08-05 US disclosed
US-20240294514-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF APOGEE PHARMACEUTICALS, INC. (CA) 2024-09-05 US disclosed
WO-2024168426-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF APOGEE PHARMACEUTICALS, INC. (CA) 2024-08-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12378231-B2 Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof MGLL, PNLIP, LPL KCNMA1 1879/4885ALDH1A1 530/4885LMNA 1479/4885
US-20240294514-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF MGLL, PNLIP, LPL KCNMA1 1879/4885ALDH1A1 530/4885LMNA 1479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.